News
BioNTech to buy rival mRNA firm CureVac for $1.25bn
BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
News
MSD aims to plug dengue fever vaccine gap in US
MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.
News
Novo Nordisk teams up with NVIDIA on AI models
Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.
News
BMS' radiopharma unit builds with $1.35bn Philochem deal
Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
News
SpliceBio gathers $135m for eye disease gene therapies
Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks